

Northern Antibiotics to present new data on key NAB compounds at the joint ICAAC/IDSA 2008

Helsinki, Finland - September 8, 2008 - Northern Antibiotics Ltd., the developer of novel polymyxin derivatives for the treatment of infections caused by multidrug-resistant Gram-negative bacteria, announced today that new data will be presented on their NAB compounds at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC on October 25-28, 2008.

There will be two poster presentations. The first one will describe the pharmacokinetic properties of the NAB compounds and the second one will show their efficacy in an animal model.

“We would like to acknowledge the efforts of the excellent scientists from Monash University, Melbourne, Australia, and Statens Serum Institut, Copenhagen, Denmark, who generated the data summarized in these posters”, stated **Professor Martti Vaara**, CEO and co-founder of Northern Antibiotics Ltd.

The presentation details are as follows:

Presentation Number: F1-3997

Presentation Title: Pharmacokinetics (PK) of Novel Anti-Gram-negative (G-) Antibiotics in Rats

Authors: F. E. A. ALI¹, G. CAO¹, A. POUDYAL¹, T. VAARA², R. L. NATION¹, M. VAARA², **J. LI**¹;

¹Facility for Anti-infective Drug Dev. & Innovation, Monash Univ., Melbourne, Australia, ²Northern Antibiotics Ltd, Helsinki, Finland

Session Number: 290

Session Title: Peptides and Peptide Mimetics

Session Type: Poster Session

Session Start/End Time: Tuesday, Oct 28, 2008, 11:15 AM -12:15 PM

Presentation Number: F1-3966

Presentation Title: Novel Polymyxin Derivatives are Effective in Treating Peritoneal E.coli Infection in Mice

Authors: **C. VINGSBO LUNDBERG**¹, T. VAARA², N. FRIMODT-MØLLER¹, M. VAARA²;

¹Statens Serum Inst., Copenhagen, Denmark, ²Northern Antibiotics Ltd, Helsinki, Finland

Session Number: 288

Session Title: New Classes of Membrane-Active or Cell Wall Targeting Agents

Session Type: Poster Session

Session Start/End Time: Tuesday, Oct 28, 2008, 11:15 AM -12:15 PM

About Northern Antibiotics Ltd.

Founded in 2003 and headquartered in Helsinki, Finland, Northern Antibiotics Ltd. is engaged in the discovery and development of novel antibiotics against multidrug-resistant Gram-negative bacteria. The NAB compounds are polymyxin derivatives that have less cationic charges than the polymyxins currently in clinical use. This difference is believed to result in reduced nephrotoxicity of the novel compounds. For more information, visit www.northernantibiotics.com.

Contact:

Dr. Barry Mason

Business Development Consultant

Email: barry.mason@northernantibiotics.com

Phone: +44 (0) 1625 858396

Mobile: +44 (0) 7713 261356